The role of CD40 expression in dendritic cells in cancer biology; a systematic review

Current Cancer Drug Targets

Volumn 14, Issue 7, 2014, Pages 610-620

  Lee, Gui Han ^a,b   Askari, Alan ^a   Malietzis, George ^a,b   Bernardo, David ^b   Clark, Susan K ^a   Knight, Stella C ^b   Al Hassi, Hafid Omar ^b  

^a ST MARK S HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antigen presenting cells; Cancer; CD40; CD40 ligand; Dendritic cells; Immunotherapy

Indexed keywords

CD40 ANTIGEN; CYCLOOXYGENASE 2; HLA DR ANTIGEN; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; TUMOR PROTEIN;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER TISSUE; CELL MATURATION; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; META ANALYSIS (TOPIC); MONOCYTE; NEOPLASM; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMATIC REVIEW; ANIMAL; DOWN REGULATION; IMMUNOLOGY; METABOLISM; METASTASIS; PATHOLOGY;

ANIMALS; ANTIGENS, CD40; DENDRITIC CELLS; DOWN-REGULATION; HUMANS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASMS;

EID: 84911480421     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009614666140828103253     Document Type: Article

References (59)

1. El Fakhry, Y.; Alturaihi, H.; Yacoub, D.; Liu, L.; Guo, W.; Leveille, C.; Jung, D.; Khzam, L. B.; Merhi, Y.; Wilkins, J. A.; Li, H.; Mourad, W. Functional interaction of CD154 protein with alpha5beta1 integrin is totally independent from its binding to alphaIIbbeta3 integrin and CD40 molecules. J. Biol. Chem., 2012, 287 (22), 18055-18066.
2. van Kooten, C.; Banchereau, J. CD40-CD40 ligand. J. Leuk. Biol., 2000, 67 (1), 2-17.
3. Kato, K.; Cantwell, M. J.; Sharma, S.; Kipps, T. J. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J. Clin. Invest., 1998, 101 (5), 1133-1141.
4. Pellat-Deceunynck, C.; Amiot, M.; Robillard, N.; Wijdenes, J.; Bataille, R. CD11a-CD18 and CD102 interactions mediate human myeloma cell growth arrest induced by CD40 stimulation. Cancer Res., 1996, 56 (8), 1909-1916.
5. Teoh, G.; Tai, Y. T.; Urashima, M.; Shirahama, S.; Matsuzaki, M.; Chauhan, D.; Treon, S. P.; Raje, N.; Hideshima, T.; Shima, Y.; Anderson, K. C. CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Blood, 2000, 95 (3), 1039-1046.
6. Cooke, P. W.; James, N. D.; Ganesan, R.; Wallace, M.; Burton, A.; Young, L. S., CD40 expression in bladder cancer. J. Pathol., 1999, 188, (1), 38-43.
7. Wingett, D. G.; Vestal, R. E.; Forcier, K.; Hadjokas, N.; Nielson, C. P. CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res. Tr., 1998, 50 (1), 27-36.
8. Gallagher, N. J.; Eliopoulos, A. G.; Agathangelo, A.; Oates, J.; Crocker, J.; Young, L. S. CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion. Mol. Pathol.: MP, 2002, 55 (2), 110-120.
9. Grewal, I. S.; Flavell, R. A. CD40 and CD154 in cell-mediated immunity. Annual Rev. Immunol., 1998, 16, 111-135.
10. Banchereau, J.; Briere, F.; Caux, C.; Davoust, J.; Lebecque, S.; Liu, Y. J.; Pulendran, B.; Palucka, K. Immunobiology of dendritic cells. Annual Rev. Immunol., 2000, 18, 767-811.
11. Diaconu, I.; Cerullo, V.; Hirvinen, M. L.; Escutenaire, S.; Ugolini, M.; Pesonen, S. K.; Bramante, S.; Parviainen, S.; Kanerva, A.; Loskog, A. S.; Eliopoulos, A. G.; Pesonen, S.; Hemminki, A. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res., 2012, 72, (9), 2327-2338.
12. Mackey, M. F.; Gunn, J. R.; Maliszewsky, C.; Kikutani, H.; Noelle, R. J.; Barth, R. J., Jr. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J. Immunol., 1998, 161 (5), 2094-2098.
13. Sallusto, F.; Lanzavecchia, A. Mobilizing dendritic cells for tolerance, priming, and chronic inflammation. J. Exp. Med., 1999, 189 (4), 611-614.
14. Bakdash, G.; Sittig, S. P.; van Dijk, T.; Figdor, C. G.; de Vries, I. J. The nature of activatory and tolerogenic dendritic cell-derived signal II. Front. Immunol., 2013, 4, 53.
15. van Mierlo, G. J.; den Boer, A. T.; Medema, J. P.; van der Voort, E. I.; Fransen, M. F.; Offringa, R.; Melief, C. J.; Toes, R. E. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. P. Natl. Acad. Sci. U. S. A., 2002, 99 (8), 5561-5566.
16. Vonderheide, R. H. Prospect of targeting the CD40 pathway for cancer therapy. Clin. Cancer Res., 2007, 13 (4), 1083-1088.
17. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D. G.; Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med., 2009, 6 (7), e1000097.
18. Schwaab, T.; Schned, A. R.; Heaney, J. A.; Cole, B. F.; Atzpodien, J.; Wittke, F.; Ernstoff, M. S. In vivo description of dendritic cells in human renal cell carcinoma. J. Urol., 1999, 162 (2), 567-573.
19. Bennaceur, K.; Popa, I.; Portoukalian, J.; Berthier-Vergnes, O.; Peguet-Navarro, J. Melanoma-derived gangliosides impair migratory and antigen-presenting function of human epidermal Langerhans cells and induce their apoptosis. Int. Immunol., 2006, 18 (6), 879-886.
20. Schwaab, T.; Weiss, J. E.; Schned, A. R.; Barth, R. J., Jr. Dendritic cell infiltration in colon cancer. J. Immunother., 2001, 24 (2), 130-137.
21. Matsuura, K.; Yamaguchi, Y.; Ueno, H.; Osaki, A.; Arihiro, K.; Toge, T. Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer, 2006, 106 (6), 1227-1236.
22. Jia, J.; Wang, Z.; Li, X.; Wang, Z.; Wang, X. Morphological characteristics and co-stimulatory molecule (CD80, CD86, CD40) expression in tumor infiltrating dendritic cells in human endometrioid adenocarcinoma. Eur. J. Obstet. Gynecol. Reprod. Biol, 2012, 160 (2), 223-227.
23. Bellone, G.; Carbone, A.; Smirne, C.; Scirelli, T.; Buffolino, A.; Novarino, A.; Stacchini, A.; Bertetto, O.; Palestro, G.; Sorio, C.; Scarpa, A.; Emanuelli, G.; Rodeck, U. Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J. Immunol., 2006, 177 (5), 3448-3460.
24. Hou, M. M.; Chang, J. W.; Pang, S. T.; Chiang, Y. J.; Shen, Y. C.; Liao, S. K.; Hsieh, J. J.; Yeh, K. Y.; Chang, N. J.; Chuang, C. K. Characterization of the response of dendritic cells and regulatory T cells to tumor antigens in patients with renal cell carcinoma. Chang Gung Med. J., 2010, 33 (1), 25-35.
25. Hasebe, H.; Nagayama, H.; Sato, K.; Enomoto, M.; Takeda, Y.; Takahashi, T. A.; Hasumi, K.; Eriguchi, M. Dysfunctional regulation of the development of monocyte-derived dendritic cells in cancer patients. Biomed. Pharmacother., 2000 54 (6), 291-298.
26. Tjomsland, V.; Spangeus, A.; Sandstrom, P.; Borch, K.; Messmer, D.; Larsson, M. Semi mature blood dendritic cells exist in patients with ductal pancreatic adenocarcinoma owing to inflammatory factors released from the tumor. PloS One, 2010, 5 (10), e13441.
27. Pinzon-Charry, A.; Ho, C. S.; Laherty, R.; Maxwell, T.; Walker, D.; Gardiner, R. A.; O'Connor, L.; Pyke, C.; Schmidt, C.; Furnival, C.; Lopez, J. A. A population of HLA-DR+ immature cells accumulates in the blood dendritic cell compartment of patients with different types of cancer. Neoplasia, 2005, 7 (12), 1112-1122.
28. Kalady, M. F.; Onaitis, M. W.; Emani, S.; Abdul-Wahab, Z.; Pruitt, S. K.; Tyler, D. S. Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells. J. Gastrointest. Surg., 2004, 8 (2), 175-181; discussion 181-172.
29. Pockaj, B. A.; Basu, G. D.; Pathangey, L. B.; Gray, R. J.; Hernandez, J. L.; Gendler, S. J.; Mukherjee, P. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann. Surg. Oncol., 2004, 11 (3), 328-339.
30. Pinzon-Charry, A.; Ho, C. S.; Maxwell, T.; McGuckin, M. A.; Schmidt, C.; Furnival, C.; Pyke, C. M.; Lopez, J. A. Numerical and functional defects of blood dendritic cells in early-and late-stage breast cancer. Brit. J. Cancer, 2007, 97 (9), 1251-1259.
31. Viac, J.; Schmitt, D.; Claudy, A. CD40 expression in epidermal tumors. Anticancer Res., 1997, 17 (1B), 569-572.
32. Amo, Y.; Ohta, Y.; Hamada, Y.; Tatsuta, M.; Katsuoka, K. Expression of CD40 and CD40 ligand in Bowen's disease and squamous cell carcinoma. Eur. J. Dermatol., 2000, 10 (6), 439-442.
33. Essner, R.; Kojima, M. Surgical and molecular approaches to the sentinel lymph nodes. Ann. Surg. Oncol., 2001, 8, (9 Suppl), 31S-34S.
34. Scarpino, S.; Stoppacciaro, A.; Ballerini, F.; Marchesi, M.; Prat, M.; Stella, M. C.; Sozzani, S.; Allavena, P.; Mantovani, A.; Ruco, L. P. Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am. J. Pathol., 2000, 156 (3), 831-837.
35. Seo, M. J.; Kim, G. R.; Son, Y. M.; Yang, D. C.; Chu, H.; Min, T. S.; Jung, I. D.; Park, Y. M.; Han, S. H.; Yun, C. H. Interactions of dendritic cells with cancer cells and modulation of surface molecules affect functional properties of CD8+ T cells. Mol. Immunol., 2011, 48 (15-16), 1744-1752.
36. Bekeredjian-Ding, I.; Schafer, M.; Hartmann, E.; Pries, R.; Parcina, M.; Schneider, P.; Giese, T.; Endres, S.; Wollenberg, B.; Hartmann, G. Tumour-derived prostaglandin E and transforming growth factor-beta synergize to inhibit plasmacytoid dendritic cell-derived interferon-alpha. Immunology, 2009, 128 (3), 439-450.
37. Zavadova, E.; Savary, C. A.; Templin, S.; Verschraegen, C. F.; Freedman, R. S., Maturation of dendritic cells from ovarian cancer patients. Cancer Chem. Pharm., 2001, 48, (4), 289-296.
38. Condamine, T.; Kumar, V.; Ramachandran, I. R.; Youn, J. I.; Celis, E.; Finnberg, N.; El-Deiry, W. S.; Winograd, R.; Vonderheide, R. H.; English, N. R.; Knight, S. C.; Yagita, H.; McCaffrey, J. C.; Antonia, S.; Hockstein, N.; Witt, R.; Masters, G.; Bauer, T.; Gabrilovich, D. I. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J. Clin. Invest., 2014.
39. Monti, P.; Leone, B. E.; Zerbi, A.; Balzano, G.; Cainarca, S.; Sordi, V.; Pontillo, M.; Mercalli, A.; Di Carlo, V.; Allavena, P.; Piemonti, L., Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10highIL-12low regulatory dendritic cell. J. Immunol., 2004, 172 (12), 7341-7349.
40. Sato, K.; Nagayama, H.; Tadokoro, K.; Juji, T.; Takahashi, T. A., Extracellular signal-regulated kinase, stress-activated protein kinase/c-Jun N-terminal kinase, and p38mapk are involved in IL-10-mediated selective repression of TNF-alpha-induced activation and maturation of human peripheral blood monocyte-derived dendritic cells. J. Immunol., 1999, 162 (7), 3865-3872.
41. Bhattacharyya, S.; Sen, P.; Wallet, M.; Long, B.; Baldwin, A. S., Jr.; Tisch, R. Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of IkappaB kinase activity. Blood, 2004, 104 (4), 1100-1109.
42. Sallusto, F.; Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med., 1994, 179 (4), 1109-1118.
43. Collin, M.; Bigley, V.; Haniffa, M.; Hambleton, S. Human dendritic cell deficiency: the missing ID? Nat. Rev. Immunol., 2011, 11 (9), 575-583.
44. Shortman, K.; Liu, Y. J. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol., 2002, 2 (3), 151-161.
45. Bernardo, D.; Mann, E. R.; Al-Hassi, H. O.; English, N. R.; Man, R.; Lee, G. H.; Ronde, E.; Landy, J.; Peake, S. T.; Hart, A. L.; Knight, S. C. Lost therapeutic potential of monocyte-derived DC through lost tissue homing; stable restoration of gut specificity with retinoic acid. Clin. Exp. Immunol., 2013.
46. Davison, G. M.; Novitzky, N.; Abdulla, R. Monocyte derived dendritic cells have reduced expression of co-stimulatory molecules but are able to stimulate autologous T-cells in patients with MDS. Hematol Oncol. Stem Cell Ther., 2013, 6 (2), 49-57.
47. Grassi, F.; Dezutter-Dambuyant, C.; McIlroy, D.; Jacquet, C.; Yoneda, K.; Imamura, S.; Boumsell, L.; Schmitt, D.; Autran, B.; Debre, P.; Hosmalin, A. Monocyte-derived dendritic cells have a phenotype comparable to that of dermal dendritic cells and display ultrastructural granules distinct from Birbeck granules. J. Leuk. Biol., 1998, 64 (4), 484-493.
48. MacDonald, K. P.; Munster, D. J.; Clark, G. J.; Dzionek, A.; Schmitz, J.; Hart, D. N. Characterization of human blood dendritic cell subsets. Blood, 2002, 100 (13), 4512-4520.
49. Lechmann, M.; Berchtold, S.; Hauber, J.; Steinkasserer, A. CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol., 2002, 23 (6), 273-275.
50. Scholler, N.; Hayden-Ledbetter, M.; Dahlin, A.; Hellstrom, I.; Hellstrom, K. E.; Ledbetter, J. A. Cutting edge: CD83 regulates the development of cellular immunity. J. Immunol., 2002, 168 (6), 2599-2602.
51. Segerer, S.; Heller, F.; Lindenmeyer, M. T.; Schmid, H.; Cohen, C. D.; Draganovici, D.; Mandelbaum, J.; Nelson, P. J.; Grone, H. J.; Grone, E. F.; Figel, A. M.; Nossner, E.; Schlondorff, D. Compartment specific expression of dendritic cell markers in human glomerulonephritis. Kidney Int., 2008, 74 (1), 37-46.
52. Thomachot, M. C.; Bendriss-Vermare, N.; Massacrier, C.; Biota, C.; Treilleux, I.; Goddard, S.; Caux, C.; Bachelot, T.; Blay, J. Y.; Menetrier-Caux, C. Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1a(high)CD86(-)Langerin-and CD1a(+)CD86(+)Langerin+ phenotypes. Int. J. Cancer, 2004, 110, (5), 710-720.
53. Jackaman, C.; Lew, A. M.; Zhan, Y.; Allan, J. E.; Koloska, B.; Graham, P. T.; Robinson, B. W.; Nelson, D. J. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int. Immunol., 2008, 20, (11), 1467-1479.
54. Vonderheide, R. H.; Glennie, M. J. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res., 2013, 19 (5), 1035-1043.
55. Vonderheide, R. H.; Flaherty, K. T.; Khalil, M.; Stumacher, M. S.; Bajor, D. L.; Hutnick, N. A.; Sullivan, P.; Mahany, J. J.; Gallagher, M.; Kramer, A.; Green, S. J.; O'Dwyer, P. J.; Running, K. L.; Huhn, R. D.; Antonia, S. J. Clinical activity and immune modulation in cancer patients treated with CP-870, 893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol., 2007, 25 (7), 876-883.
56. Beatty, G. L.; Torigian, D. A.; Chiorean, E. G.; Saboury, B.; Brothers, A.; Alavi, A.; Troxel, A. B.; Sun, W.; Teitelbaum, U. R.; Vonderheide, R. H.; O'Dwyer, P. J. A phase I study of an agonist CD40 monoclonal antibody (CP-870, 893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin. Cancer Res., 2013, 19 (22), 6286-6295.
57. Khong, A.; Nelson, D. J.; Nowak, A. K.; Lake, R. A.; Robinson, B. W. The use of agonistic anti-CD40 therapy in treatments for cancer. Int. Rev. Immunol., 2012, 31 (4), 246-266.
58. Hassan, S. B.; Sorensen, J. F.; Olsen, B. N.; Pedersen, A. E., Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharm. Immunotoxicol., 2014, 36 (2), 96-104.
59. Liljenfeldt, L.; Gkirtzimanaki, K.; Vyrla, D.; Svensson, E.; Loskog, A. S.; Eliopoulos, A. G. Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand. Cancer Immunol. Immunother. CII, 2014, 63 (3), 273-282.